Using machine learning to estimate time-to-progression in ovarian cancer based on cancer registry and administrative health data
Authors:
- A. LeloupALA. Leloup
- J. VerbeeckJVJ. Verbeeck
- H. De SchutterHSH. De Schutter
- M. ThibautMTM. Thibaut
- J.F. BaurainJBJ.F. Baurain
- S. HenrySHS. Henry
- Z. HlavataZHZ. Hlavata
- T. LagaTLT. Laga
- S. MarquetteSMS. Marquette
- P. NevenPNP. Neven
- L. PolastroLPL. Polastro
- A. VandersticheleAVA. Vanderstichele
Open Access
- 5 October 2026
- journal article
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 14
Abstract
No abstract availableFunding Information
- Fondation contre le Cancer
- Stichting Tegen Kanker (2023-003)
This publication has 17 references indexed in Scilit:
- Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Estimating the incidence of breast cancer recurrence using administrative dataBreast Cancer Research and Treatment, 2022
- A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative DataJNCI: Journal of the National Cancer Institute, 2020
- A validated algorithm for register-based identification of patients with recurrence of breast cancer—Based on Danish Breast Cancer Group (DBCG) dataCancer Epidemiology, 2019
- Advances in ovarian cancer therapyCancer Chemotherapy and Pharmacology, 2017
- Ovarian cancerNature Reviews Disease Primers, 2016
- Challenges and Opportunities in Measuring Cancer Recurrence in the United StatesJNCI: Journal of the National Cancer Institute, 2015
- Administrative Data Algorithms to Identify Second Breast Cancer Events Following Early-Stage Invasive Breast CancerJNCI: Journal of the National Cancer Institute, 2012
- The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group studyGynecologic Oncology, 2010
- Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 2006